Zimmer Biomet ZBH
Zimmer Biomet is a medical device company that designs, manufactures, and sells orthopedic implants, reconstructive surgery products, and healthcare technologies, primarily to hospitals and surgeons. Zimmer Biomet presents solid financial health (score 6.25) and an attractive valuation (score 7.2) with a forward P/E of 10.04 and a PEG of 0.57, suggesting the market does not fully discount its growth potential. Earnings growth of 33.8% is robust, although quality (ROE 6.41%) and operating margin (17.96%) are moderate.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Zimmer Biomet is a medical device company that designs, manufactures, and sells orthopedic implants, reconstructive surgery products, and healthcare technologies, primarily to hospitals and surgeons. Zimmer Biomet presents solid financial health (score 6.25) and an attractive valuation (score 7.2) with a forward P/E of 10.04 and a PEG of 0.57, suggesting the market does not fully discount its growth potential. Earnings growth of 33.8% is robust, although quality (ROE 6.41%) and operating margin (17.96%) are moderate.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.2 |
| Quality / Moat | 5.3 |
| Valuation | 7.2 |
| Growth | 7.0 |
| Dividend | 5.0 |
| Momentum | 5.5 |
| Risk & Context | 8.0 |
OVERALL SCORE: 6.4/10
Context and risks
Moderate regulatory risk in the U.S. for medical devices (pricing pressure, FDA oversight). The medical technology sector is under active regulatory review, which could affect product launches and pricing.
News considered in the analysis
- Zimmer Biomet (ZBH): Buy, Sell, or Hold Post Q2 Earnings? — Análisis genérico post-resultados sin información nueva.
- Zimmer Biomet Holdings (ZBH) Pushes Cost Reset Plans, Is It Still 17% Below Fair Value? — El plan de reducción de costes es un factor positivo moderado para márgenes futuros, aunque su ejecución aún no está garantizada.
- Can This Number Push ISRG Stock Higher? — Noticia sobre un competidor (Intuitive Surgical), no sobre ZBH.
- Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know — Titular de movimiento de precios sin información fundamental nueva.
- 3 Mid-Cap Stocks with Open Questions — Listículo genérico sin análisis específico accionable.
Verdict: Hold, with a positive bias. Valuation is attractive and the cost reduction plan could boost margins, but business quality is average and regulatory risk is a factor to watch.
Main risk: The main risk is regulatory and pricing pressure in the U.S. medical device sector, which could impact margins and the launch of new products.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →